Patritumab Deruxtecan
Gastroesophageal Adenocarcinoma
Explore 40 assets in Gastroesophageal Adenocarcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06469944CT.gov Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Patritumab Deruxtecan (this asset) | Merck Sharp & Dohme LLC | P1/2 | CC · 43 |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Pembrolizumab | Diwakar Davar | P3 | BB |
| Nivolumab | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Trastuzumab | UNICANCER | P3 | BB |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | B |
| Capecitabine | Shanghai Zhongshan Hospital | P3 | B |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | B |
| Zanidatamab | Tao Zhang | P3 | B |
+42 more in the Gastroesophageal Adenocarcinoma cohort
Other indications for Patritumab Deruxtecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Breast Neoplasm | — | P3 | B · 60 |
| Non-Small Cell Squamous Lung Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Patritumab Deruxtecan in Gastroesophageal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/patritumab-deruxtecan-gastroesophageal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →